| Date: | 11/16/2022 |
|-------------------------------|---|
| Your Name: | Fong Chin Heng |
| Manuscript Title: | Recommended first-line management of brain metastases from EGFR mutant and ALK positive NSCLC varies significantly according to specialty: An international survey of clinical practice |
| Manuscript Number (if known): | JTD-22-697-R2 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial planning | of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | Click the tab key to add additional rows. |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None | |
| 3 | Royalties or licenses | ☑ None | |

| | | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|---|---|
| 4 | Consulting fees | None | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None | |
| 6 | Payment for expert testimony | None | |
| 7 | Support for attending meetings and/or travel | None | |
| 8 | Patents planned, issued or pending | None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | |

| | | | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----------|--|--|---|---|
| 11 | Stock or stock options | | None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | | None | |
| 13 | Other financial or non-financial interests | | None | |
| Plea × | Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form. | | | |

| Date: | 11/25/2022 |
|-------------------------------|---|
| Your Name: | Nicholas Meti |
| Manuscript Title: | Recommended first-line management of brain metastases from EGFR mutant and ALK positive NSCLC varies significantly according to specialty: An international survey of clinical practice |
| Manuscript Number (if known): | JTD-22-697-R2 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| | | Time frame: Since the initial planning | of the work |
| 1 | All support for the present manuscript (e.g., | None | |
| | funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | | Click the tab key to add additional rows. |
| | | Time frame: past 36 month | IS |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|--|---|
| 3 | Royalties or licenses | None | |
| 4 | Consulting fees | None | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None Takeda Oncology Astra Zeneca | |
| 6 | Payment for expert testimony | None | |
| 7 | Support for attending meetings and/or travel | None | |
| 8 | Patents planned, issued or pending | ⊠ None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None Pfizer Novartis Seagen | |
| 10 | Leadership or fiduciary role in other board, | ⊠ None | |

| | | ame all entities with whom you have this Specifications/Comments (e.g., if payments were elationship or indicate none (add rows as needed) made to you or to your institution) | ! |
|-----------|---|--|---|
| | society, committee or advocacy group, paid or unpaid | | ļ |
| 11 | Stock or stock options | None |] |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None | |
| 13 | Other financial or non-financial interests | None | |
| Plea × | - | o the following statement to indicate your agreement: Iswered every question and have not altered the wording of any of the questions on this form. | |

| Date: | 1/13/2023 |
|-------------------------------|---|
| Your Name: | Timothy Kruser |
| Manuscript Title: | Recommended first-line management of brain metastases from EGFR mutant and ALK positive NSCLC varies significantly according to specialty: An international survey of clinical practice |
| Manuscript Number (if known): | JTD-22-697-R2 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|-------------|---|---|
| | | | Time frame: Since the initial planning | of the work |
| 1 | All support for the present manuscript (e.g., | \boxtimes | None | |
| | funding, provision | | | |
| | of study materials, | | | Click the tab key to add additional rows. |
| | medical writing, | | | Click the tab key to duu duultiondi rows. |
| | article processing | | | |
| | | | | |
| | charges, etc.) No time limit for | | | |
| | | | | |
| | this item. | | | |
| | | | Time frame: past 36 month | S |
| 2 | Grants or contracts from | \boxtimes | None | |
| | any entity (if not | | | |
| | indicated in item | | | |
| | #1 above). | | | |
| | | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|--|---|
| 3 | Royalties or licenses | ☑ None | |
| 4 | Consulting fees | None | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☑ None | |
| 6 | Payment for expert testimony | ⊠ None | |
| 7 | Support for attending meetings and/or travel | ☑ None | |
| 8 | Patents planned, issued or pending | None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | ⊠ None | |
| 10 | Leadership or fiduciary role in other board, | ⊠ None | |

| | | ame all entities with whom you have this and a specifications/Comments (e.g., if payments were lationship or indicate none (add rows as needed) made to you or to your institution) | e |
|-----------|---|---|---|
| | society, committee or advocacy group, paid or unpaid | | |
| 11 | Stock or stock options | None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None | |
| 13 | Other financial or non-financial interests | None | _ |
| Plea × | - | the following statement to indicate your agreement: | |

| Date: | 3/1/2023 |
|-------------------------------|---|
| Your Name: | Jessica Weiss |
| Manuscript Title: | Recommended first-line management of brain metastases from EGFR mutant and ALK positive NSCLC varies significantly according to specialty: An international survey of clinical practice |
| Manuscript Number (if known): | JTD-22-697-R2 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| - | | | |
|---|--|---|---|
| | | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
| | | Time frame: Since the initial planning | of the work |
| 1 | All support for the present manuscript (e.g., funding, provision | None | |
| | of study materials, medical writing, article processing charges, etc.) No time limit for this item. | | Click the tab key to add additional rows. |
| | | Time frame: past 36 month | s |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|--|---|
| 3 | Royalties or licenses | ☑ None | |
| 4 | Consulting fees | None | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☑ None | |
| 6 | Payment for expert testimony | ⊠ None | |
| 7 | Support for attending meetings and/or travel | ☑ None | |
| 8 | Patents planned, issued or pending | None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | ⊠ None | |
| 10 | Leadership or fiduciary role in other board, | ⊠ None | |

| | | ame all entities with whom you have this and a specifications/Comments (e.g., if payments were lationship or indicate none (add rows as needed) made to you or to your institution) | e |
|-----------|---|---|---|
| | society, committee or advocacy group, paid or unpaid | | |
| 11 | Stock or stock options | None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None | |
| 13 | Other financial or non-financial interests | None | _ |
| Plea × | Please place an "X" next to the following statement to indicate your agreement: | | |

| Manuscript Title: | Recommended first-line management of brain metastases from EGFR mutant and ALK positive NSCLC varies significantly according to specialty: An international survey of clinical practice |
|-------------------------------|--|
| Manuscript Title: | 5 |
| Manuscript Number (if known): | JTD-22-697-R2 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial planning | of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | Click the tab key to add additional rows. |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None | |
| 3 | Royalties or licenses | ☑ None | |

| | | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|---|---|
| 4 | Consulting fees | None | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None | |
| 6 | Payment for expert testimony | None | |
| 7 | Support for attending meetings and/or travel | None | |
| 8 | Patents planned, issued or pending | None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | |

| | | | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----------|---|--|---|---|
| 11 | Stock or stock options | | None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | | None | |
| 13 | Other financial or non-financial interests | | None | |
| Plea × | Please place an "X" next to the following statement to indicate your agreement: | | | |

| Manuscript Number (if known): | JTD-22-697-R2 |
|-------------------------------|---|
| Manuscript Title: | Recommended first-line management of brain metastases from EGFR mutant and ALK positive NSCLC varies significantly according to specialty: An international survey of clinical practice |
| Your Name: | Hirokazu Takami |
| Date: | 11/7/2022 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial planning | of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | Click the tab key to add additional rows. |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None | |
| 3 | Royalties or licenses | ☑ None | |

| | | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|---|---|
| 4 | Consulting fees | None | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None | |
| 6 | Payment for expert testimony | None | |
| 7 | Support for attending meetings and/or travel | None | |
| 8 | Patents planned, issued or pending | None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | |

| | | | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----------|---|--|---|---|
| 11 | Stock or stock options | | None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | | None | |
| 13 | Other financial or non-financial interests | | None | |
| Plea × | Please place an "X" next to the following statement to indicate your agreement: | | | |

| Date: | 1/19/2023 |
|-------------------------------|---|
| Your Name: Yoshitaka Narita | |
| Manuscript Title: | Recommended first-line management of brain metastases from EGFR mutant and ALK positive NSCLC varies significantly according to specialty: An international survey of clinical practice |
| Manuscript Number (if known): | JTD-22-697-R2 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|-------------|---|---|
| | | | Time frame: Since the initial planning | of the work |
| 1 | All support for the present manuscript (e.g., | \boxtimes | None | |
| | funding, provision | | | |
| | of study materials, | | | Click the tab key to add additional rows. |
| | medical writing, | | | Click the tab key to duu duultiondi rows. |
| | article processing | | | |
| | | | | |
| | charges, etc.) No time limit for | | | |
| | | | | |
| | this item. | | | |
| | | | Time frame: past 36 month | S |
| 2 | Grants or contracts from | \boxtimes | None | |
| | any entity (if not | | | |
| | indicated in item | | | |
| | #1 above). | | | |
| | | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|--|---|
| 3 | Royalties or licenses | ☑ None | |
| 4 | Consulting fees | None | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☑ None | |
| 6 | Payment for expert testimony | ⊠ None | |
| 7 | Support for attending meetings and/or travel | ☑ None | |
| 8 | Patents planned, issued or pending | None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | ⊠ None | |
| 10 | Leadership or fiduciary role in other board, | ⊠ None | |

| | | ame all entities with whom you have this and a specifications/Comments (e.g., if payments were lationship or indicate none (add rows as needed) made to you or to your institution) | e |
|-----------|---|---|---|
| | society, committee or advocacy group, paid or unpaid | | |
| 11 | Stock or stock options | None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None | |
| 13 | Other financial or non-financial interests | None | _ |
| Plea × | Please place an "X" next to the following statement to indicate your agreement: | | |

Date: November, 16 2022. Your Name: Fabio Y. Moraes

Manuscript Title: Recommended first-line management of asymptomatic brain metastases from EGFR mutant and ALK positive NSCLC varies significantly according to specialty: An international survey of clinical practice

Manuscript number (if known):_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | _ X_ None | |
| | manuscript (e.g., funding, | | |
| | provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated | CTAQ Queen's University | Grants or contracts from CTAQ Queen's University, unrelated to the present work. |
| | in item #1 above). | | |
| | | | |
| 3 | Royalties or licenses | _X_None | |
| | | | |
| | | | |

| 4 | Consulting fees | Elekta | Consulting fee from Cancer em foco (Elekta) outside the current work |
|----|--|-----------------------|---|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | AstraZeneca and IASLC | Honoraria from AstraZeneca and IASLC outside the current work. |
| 6 | Payment for expert testimony | _X_None | |
| 7 | Support for attending meetings and/or travel | _X_None | |
| 8 | Patents planned, issued or pending | _X_None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | _X_None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | _X_None | |
| 11 | Stock or stock options | _X_None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | _X_None | |
| 13 | Other financial or non- financial interests | _X_None | |

Please place an "X" next to the following statement to indicate your agreement:

__X__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

| Date: | 11/6/2022 |
|-------------------------------|---|
| Your Name: | Archya Dasgupta |
| Manuscript Title: | Recommended first-line management of brain metastases from EGFR mutant and ALK positive NSCLC varies significantly according to specialty: An international survey of clinical practice |
| Manuscript Number (if known): | JTD-22-697-R2 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | Time frame: Since the initial planning of the work | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | Click the tab key to add additional rows. |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None | |
| 3 | Royalties or licenses | ☑ None | |

| | | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|---|---|
| 4 | Consulting fees | None | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None | |
| 6 | Payment for expert testimony | None | |
| 7 | Support for attending meetings and/or travel | None | |
| 8 | Patents planned, issued or pending | None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | |

| | | | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----------|---|--|---|---|
| 11 | Stock or stock options | | None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | | None | |
| 13 | Other financial or non-financial interests | | None | |
| Plea × | Please place an "X" next to the following statement to indicate your agreement: | | | |

| Date: | 12/22/2022 | |
|-------------------------------|---|--|
| Your Name: | Choo Khoon ONG | |
| Manuscript Title: | Recommended first-line management of brain metastases from EGFR mutant and ALK positive NSCLC varies significantly according to specialty: An international survey of clinical practice | |
| Manuscript Number (if known): | JTD-22-697-R2 | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| - | | | |
|---|--|---|---|
| | | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
| | | Time frame: Since the initial planning | of the work |
| 1 | All support for the present manuscript (e.g., funding, provision | None | |
| | of study materials, medical writing, article processing charges, etc.) No time limit for this item. | | Click the tab key to add additional rows. |
| | | Time frame: past 36 month | s |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|--|---|
| 3 | Royalties or licenses | ☑ None | |
| 4 | Consulting fees | None | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None | |
| 6 | Payment for expert testimony | None | |
| 7 | Support for attending meetings and/or travel | ☑ None | |
| 8 | Patents planned, issued or pending | None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None | |
| 10 | Leadership or fiduciary role in other board, | ⊠ None | |

| | | ame all entities with whom you have this Specifications/Comments (e.g., if payments wer lationship or indicate none (add rows as needed) made to you or to your institution) | e |
|---|---|--|---|
| | society, committee or advocacy group, paid or unpaid | | |
| 11 | Stock or stock options | ✓ None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None | |
| 13 | Other financial or non-financial interests | None | |
| Please place an "X" next to the following statement to indicate your agreement: | | | |

Date:_____ 9/27/2022 _____ Your Name: James Chih-Hsin Yang

Manuscript Title: ____ Recommended first-line management of asymptomatic brain metastases from EGFR mutant and ALK positive NSCLC varies significantly according to specialty: An international survey of clinical practice _____ Manuscript number (if known): ______

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | Astra Zeneca | |
| З | Royalties or licenses | XNone | |
| 4 | Consulting fees | XNone | |

| | 1 | | |
|----|------------------------------|-----------------------|--|
| | | | |
| | | | |
| 5 | Payment or honoraria for | XNone | |
| | lectures, presentations, | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | X None | |
| | testimony | | |
| | | | |
| 7 | Support for attending | XNone | |
| , | meetings and/or travel | | |
| | incettings und/or traver | | |
| | | | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | XNone | |
| | pending | | |
| | | | |
| | | | |
| 9 | Participation on a Data | Amgen | |
| | Safety Monitoring Board or | Astra Zeneca | |
| | Advisory Board | Bayer | |
| | | Boehringer Ingelheim | |
| | | Bristol Myers Squibb | |
| | | Daiichi Sankyo | |
| | | Eli Lilly | |
| | | Merck | |
| | | Novartis | |
| | | Ono Pharmaceuticals | |
| | | Pfizer | |
| | | Roche/Genentech | |
| | | Takeda | |
| | | | |
| | | Yuhan Pharmaceuticals | |
| | | JNJ | |
| | | Puma Technolog | |
| | | Gilead | |
| | | GSK | |
| 10 | Leadership or fiduciary role | XNone | |
| | in other board, society, | | |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | XNone | |
| | | | |
| | | | |
| 12 | Dessint of any interview | V News | |
| 12 | Receipt of equipment, | X_None | |
| | materials, drugs, medical | | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | XNone | |
| 10 | financial interests | | |
| | indicial interests | | |

Please summarize the above conflict of interest in the following box:

JCHY reports participation in advisory board with Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Merck, Novartis, Ono Pharmaceuticals, Pfizer, Roche/Genentech, Takeda, Yuhan Pharmaceuticals, JNJ, Puma Technology, Gilead, and GSK; grant support with Astra Zeneca.

Please place an "X" next to the following statement to indicate your agreement:

__X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

| Manuscript Number (if known): | JTD-22-697-R2 |
|-------------------------------|---|
| Manuscript Title: | Recommended first-line management of brain metastases from EGFR mutant and ALK positive NSCLC varies significantly according to specialty: An international survey of clinical practice |
| Your Name: | Jih-Hsiang Lee |
| Date: | 11/4/2022 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|--|---|---|---|
| Time frame: Since the initial planning of the work | | | ; of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None ✓ None ✓ ✓ ✓ | Click the tab key to add additional rows. |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | ⊠ None | |
| 3 | Royalties or licenses | None | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|--|---|
| 4 | Consulting fees | None Pfizer | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None Bayer Pfizer Daiichi-Sankyo Novartis Boehringer Ingelheim | |
| 6 | Payment for expert testimony | None | |
| 7 | Support for attending meetings and/or travel | ☑ None | |
| 8 | Patents planned, issued or pending | ⊠ None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None Novartis Takeda Eli Lilly Astrazeneca | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | |

| | | | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|---|
| 11 | Stock or stock options | | None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | | None | |
| 13 | Other financial or non-financial interests | | None | |
| Please place an "X" next to the following statement to indicate your agreement: | | | | |

| Date: | 11/6/2022 |
|-------------------------------|---|
| Your Name: | Natalya Kosyak |
| Manuscript Title: | Recommended first-line management of brain metastases from EGFR mutant and ALK positive NSCLC varies significantly according to specialty: An international survey of clinical practice |
| Manuscript Number (if known): | JTD-22-697-R2 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|--|---|---|---|
| Time frame: Since the initial planning of the work | | | ; of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None Image: Second state Image: Second state Time frame: past 36 mont | Click the tab key to add additional rows. |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | ☑ None | |
| 3 | Royalties or licenses | None | |

| | | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|---|---|
| 4 | Consulting fees | None | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None | |
| 6 | Payment for expert testimony | None | |
| 7 | Support for attending meetings and/or travel | None | |
| 8 | Patents planned, issued or pending | None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | |

| | | | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|---|
| 11 | Stock or stock options | | None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | | None | |
| 13 | Other financial or non-financial interests | | None | |
| Please place an "X" next to the following statement to indicate your agreement: | | | | |

| Date: | 11/25/2022 | |
|-------------------------------|---|--|
| Your Name: | Nick Pavlakis | |
| Manuscript Title: | Recommended first-line management of brain metastases from EGFR mutant and ALK positive NSCLC varies significantly according to specialty: An international survey of clinical practice | |
| Manuscript Number (if known): | JTD-22-697-R2 | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| | | Time frame: Since the initial planning o | of the work |
| 1 | All support for the present manuscript (e.g., funding, provision | None | |
| | of study materials, medical writing, article processing charges, etc.) No time limit for this item. | | Click the tab key to add additional rows. |
| | | Time frame: past 36 months | s |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| 3 | Royalties or licenses | ☑ None | |
| 4 | Consulting fees | None | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | NoneBoehringer IngelheimPfizerRocheTakedaPierre-Faber | |
| 6 | Payment for expert testimony | ☑ None | |
| 7 | Support for attending meetings and/or travel | ⊠ None | |
| 8 | Patents planned, issued or pending | ☑ None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None Boehringer Ingelheim MSD Merck BMS Astra Zeneca, AllVascular Takeda, Pfizer, Roche, Amgen, Beigene, Novartis | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed)Specifications/Comments (e.g., if payments wer made to you or to your institution) | e | |
|-----------|---|--|---|--|
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | | |
| 11 | Stock or stock options | ☑ None | | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None | | |
| 13 | Other financial or non-financial interests | None Research funding to Institution from Bayer, Pfizer and Roche | | |
| Plea × | Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form. | | | |

| Date: | 1/20/2023 | |
|-------------------------------|---|--|
| Your Name: | Paul Kongkham | |
| Manuscript Title: | Recommended first-line management of brain metastases from EGFR mutant and ALK positive NSCLC varies significantly according to specialty: An international survey of clinical practice | |
| Manuscript Number (if known): | JTD-22-697-R2 | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| - | | | |
|---|--|---|---|
| | | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
| | | Time frame: Since the initial planning | of the work |
| 1 | All support for the present manuscript (e.g., funding, provision | None | |
| | of study materials, medical writing, article processing charges, etc.) No time limit for this item. | | Click the tab key to add additional rows. |
| | | Time frame: past 36 month | s |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None | |

| | | Name all entities with whom you have thisSpecifications/Comments (e.g., if payments viewrelationship or indicate none (add rows as needed)made to you or to your institution) | were |
|----|---|--|------|
| 3 | Royalties or licenses | None | |
| 4 | Consulting fees | ☑ None | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None | |
| 6 | Payment for expert testimony | ⊠ None | |
| 7 | Support for attending meetings and/or travel | ☑ None ☑ □ ☑ □ ☑ □ ☑ □ | |
| 8 | Patents planned, issued or pending | None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None Image: State of the | |
| 10 | Leadership or fiduciary role in other board, | ⊠ None | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| | society, committee or advocacy group, paid or unpaid | | |
| 11 | Stock or stock options | ⊠ None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☑ None | |
| 13 | Other financial or non-financial interests | None Financial compensation for administration of teaching course for the use of 5-aminolevulinic acid for fluorescent-guided resection of gliomas from Medexus pharmaceuticals Canada. | |
| Please place an "X" next to the following statement to indicate your agreement: | | | |

| Date: | 6/1/2023 | |
|-------------------------------|---|--|
| Your Name: | Mark Doherty | |
| Manuscript Title: | Recommended first-line management of brain metastases from EGFR mutant and ALK positive NSCLC varies significantly according to specialty: An international survey of clinical practice | |
| Manuscript Number (if known): | JTD-22-697-R2 | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|-------------|---|---|
| | | | Time frame: Since the initial planning | of the work |
| 1 | All support for the present manuscript (e.g., | \boxtimes | None | |
| | funding, provision | | | |
| | of study materials, | | | Click the tab key to add additional rows. |
| | medical writing, | | | Click the tab key to duu duultiondi rows. |
| | article processing | | | |
| | | | | |
| | charges, etc.) No time limit for | | | |
| | | | | |
| | this item. | | | |
| | | | Time frame: past 36 month | S |
| 2 | Grants or contracts from | \boxtimes | None | |
| | any entity (if not | | | |
| | indicated in item | | | |
| | #1 above). | | | |
| | | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| 3 | Royalties or licenses | ☑ None | |
| 4 | Consulting fees | None Roche AstraZeneca Takeda Eisai Merck | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None Roche AstraZeneca | |
| 6 | Payment for expert testimony | ☑ None | |
| 7 | Support for attending meetings and/or travel | ☑ None | |
| 8 | Patents planned, issued or pending | None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | ☑ None | |

| | | | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----------|---|--|---|---|
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | | None | |
| 11 | Stock or stock options | | None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | | None | |
| 13 | Other financial or non-financial interests | | None | |
| Plea × | Please place an "X" next to the following statement to indicate your agreement: | | | |

| Manuscript Number (if known): | JTD-22-697-R2 |
|-------------------------------|---|
| Manuscript Title: | Recommended first-line management of brain metastases from EGFR mutant and ALK positive NSCLC varies significantly according to specialty: An international survey of clinical practice |
| Your Name: | Natasha Leighl |
| Date: | 11/4/2022 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| | Time frame: Since the initial planning of the work | | |
| 1 All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | Click the tab key to add additional rows. | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None | |
| 3 | Royalties or licenses | ☑ None | |

| | | Name all entities with whom you have thisSpecifications/Commerelationship or indicate none (add rows as needed)made to you or to you | ents (e.g., if payments were r institution) |
|----|---|--|--|
| 4 | Consulting fees | ☑ None | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None Amgen, Astra Zeneca, BMS, Janssen, MSD, Novartis, Pfizer, Roche, Sanofi, Takeda | ures (unrelated) |
| 6 | Payment for expert testimony | None | |
| 7 | Support for attending meetings and/or travel | ☑ None | |
| 8 | Patents planned, issued or pending | ☑ None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | ☑ None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☑ None | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) | |
|-----------|---|--|---|--|
| 11 | Stock or stock options | ☑ None | | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ⊠ None | | |
| 13 | Other financial or non-financial interests | None Amgen, Array, Astra Zeneca, Bayer, BMS, Eli Lilly, EMD Serono, Guardant Health, Inivata, Janssen, MSD, Novartis, Pfizer, Roche, Takeda | Institutional research funding (unrelated) | |
| Plea × | Please place an "X" next to the following statement to indicate your agreement: | | | |

| Manuscript Number (if known): | JTD-22-697-R2 |
|-------------------------------|---|
| Manuscript Title: | Recommended first-line management of brain metastases from EGFR mutant and ALK positive NSCLC varies significantly according to specialty: An international survey of clinical practice |
| Your Name: | David Shultz |
| Date: | 11/4/2022 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| | Time frame: Since the initial planning of the work | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None Image: Second state Image: Second state Time frame: past 36 mont | Click the tab key to add additional rows. |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | ☑ None | |
| 3 | Royalties or licenses | None | |

| | | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|---|---|
| 4 | Consulting fees | None | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None | |
| 6 | Payment for expert testimony | None | |
| 7 | Support for attending meetings and/or travel | None | |
| 8 | Patents planned, issued or pending | None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | |

| | | | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|---|
| 11 | Stock or stock options | | None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | | None | |
| 13 | Other financial or non-financial interests | | None | |
| Please place an "X" next to the following statement to indicate your agreement: | | | | |